Dasatinib 70 mg/1 (Dasatinib TABLET, FILM COATED) 70 mg/1

Dasatinib 70 mg tablets are a prescription medication used to treat certain types of cancer. This oral medication is designed to target specific proteins involved in cancer cell growth.

Strength

70 mg/1

Pack Size

60 TABLET, FILM COATED in 1 BOTTLE (0480-5103-06)

Manufacturer / TM Owner

Teva Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Dasatinib is primarily used in the treatment of specific types of leukemia and other cancers. It works by inhibiting the activity of proteins that promote cancer cell proliferation. Patients often wonder, 'What is Dasatinib used for?' This medication is typically prescribed for conditions where these proteins are overactive, contributing to the growth of cancer cells.

Side Effects

Common effects of Dasatinib may include fatigue, nausea, and skin rash. Some users also report muscle pain and fluid retention. These effects can vary widely among individuals and are not experienced by everyone who takes the medication.

Precautions & Warnings

Dasatinib should be handled with care, following the guidance of a healthcare provider. It is important to store the medication properly and to be aware of potential side effects. Patients should inform their healthcare provider about any pre-existing conditions or other medications they are taking.

Avoid Interactions

Dasatinib may interact with certain medications, including those that are metabolized by the liver. It is advisable to avoid grapefruit and grapefruit juice, as they can affect the metabolism of Dasatinib. Always consult a healthcare provider before starting or stopping any medication.

Frequently Asked Questions

Dasatinib is used to treat certain types of leukemia and other cancers by targeting specific proteins involved in cancer cell growth.

Dasatinib is typically taken orally, with or without food, as directed by a healthcare provider.

Common side effects may include fatigue, nausea, skin rash, muscle pain, and fluid retention.

Dasatinib may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

The safety of long-term use of Dasatinib should be discussed with a healthcare provider, who can provide personalized advice based on individual health conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.